Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

Alzheimer s Research & Therapy, Год журнала: 2024, Номер 16(1)

Опубликована: Июнь 26, 2024

Abstract Background Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance practice is unknown. Methods We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture routine a specialized memory clinic (66 cognitively unimpaired, 130 with mild cognitive impairment, 94 dementia). Participants were classified as amyloid positive (A +) or negative (A-) according to CSF Aβ 1–42 /Aβ 1–40 ratio. Plasma pTau 217 , 181 measured the fully-automated LUMIPULSE platform. used linear regression compare biomarkers concentrations between A + A- groups, evaluated Spearman’s correlation performed ROC analyses assess diagnostic detect brain amyloidosis determined by concordance of amyloidosis. Results concentration higher than while ratio was lower compared A-. showed moderate (Rho = 0.66 0.69, respectively). The areas under curve discriminate 0.94 (95% CI 0.92–0.97) 0.88 0.84–0.92) both . Chronic kidney (CKD) related increased biomarker concentrations, ratios less affected. had highest fold change (× 3.2) predictive capability discriminating A-, having 4–7% misclassification rate. global using two-threshold approach robust symptomatic exceeding 90%. Conclusion evaluation on an automated platform exhibited AD pathophysiology, excellent identify sample representing unit.

Язык: Английский

---

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Clinical Chemistry and Laboratory Medicine (CCLM), Год журнала: 2024, Номер 62(6), С. 1063 - 1069

Опубликована: Янв. 22, 2024

Abstract Alzheimer’s disease (AD), a primary cause of dementia globally, is traditionally diagnosed via cerebrospinal fluid (CSF) measures and positron emission tomography (PET). The invasiveness, cost, limited accessibility these methods have led to exploring blood-based biomarkers as promising alternative for AD diagnosis monitoring. Recent advancements in sensitive immunoassays identified potential biomarkers, such Aβ42/Aβ40 ratios phosphorylated tau (p-tau) species. This paper briefly evaluates the clinical utility reliability across various stages, highlighting challenges like refining plasma assays enhancing precision p-tau, particularly p-tau181, p-tau217, p-tau231. discussion also covers other neurofilament light (NfL), glial fibrillary acidic protein (GFAP), synaptic assessing their significance diagnostics. need ongoing research development robust match performance CSF PET underscored. In summary, are increasingly crucial diagnosis, follow-up, prognostication, treatment response evaluation, population screening, care settings. These developments set revolutionize diagnostics, offering earlier more accessible detection management options.

Язык: Английский

---

Alzheimer’s disease biomarkers and their current use in clinical research and practice

Molecular Psychiatry, Год журнала: 2024, Номер unknown

Опубликована: Сен. 4, 2024

Язык: Английский

---

Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(3), С. 1481 - 1481

Опубликована: Янв. 25, 2024

Plasma biomarkers for Alzheimer’s disease (AD) are a promising tool that may help in early diagnosis. However, their levels be influenced by physiological parameters and comorbidities should considered before they can used at the population level. For this purpose, we assessed influences of different on AD plasma markers 208 cognitively unimpaired subjects. We analyzed both cerebrospinal fluid Aβ40, Aβ42, p-tau181 using fully automated Lumipulse platform. The relationships between variables were studied linear regression models. mean differences according to comorbidity groups also studied. glomerular filtration rate showed an influence Aβ40 Aβ42 but not Aβ42/Aβ40 ratio. amyloid ratio was significantly lower diabetic hypertensive subjects, higher have inverse relationship ratio, suggesting latter is more stable marker use general population. Cardiovascular risk factors might long-term effect p-tau181.

Язык: Английский

---

Surface-Enhanced Raman Scattering Nanosensing and Imaging in Neuroscience

ACS Nano, Год журнала: 2024, Номер 18(34), С. 22620 - 22647

Опубликована: Авг. 1, 2024

Monitoring neurochemicals and imaging the molecular content of brain tissues

Язык: Английский

---

Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practice

Alzheimer s & Dementia, Год журнала: 2025, Номер unknown

Опубликована: Янв. 30, 2025

Abstract INTRODUCTION With the advancement of disease‐modifying therapies for Alzheimer's disease (AD), validating plasma biomarkers against cerebrospinal fluid (CSF) and positron emission tomography (PET) standards is crucial in both research real‐world settings. METHODS We measured phosphorylated tau (p‐tau)217, p‐tau181, amyloid beta (Aβ)1‐40, Aβ1‐42, neurofilament light chain cohorts. Participants were categorized by brain status using US Food Drug Administration/European Medicines Agency–approved CSF or PET methods. RESULTS Plasma p‐tau217 p‐tau217/Aβ1‐42 demonstrated superior accuracy detecting pathologies, with area under curve from 0.94 to 0.97 all Specificity was lower cohort but improved significantly integrating demographic clinical factors, aligning performance Additionally, exhibited strong correlations their counterparts standardized uptake value ratios, significant associations amyloid‐positive participants. DISCUSSION are effective diagnostic tools. However, patient demographics, apolipoprotein E ε4 status, cognitive condition must be considered improve specificity practice. Highlights (p‐tau)217 p‐tau217/amyloid (Aβ)1‐42 exceptional (area curve: 0.94–0.97) pathologies across (Southern China Aging Brain Initiative [SCABI]‐1, SCABI‐2) practice (RCP) Incorporating patient‐specific factors (sex, age, ε4, status) RCP cohort, its that biomarkers, particularly showed robust underscoring as non‐invasive alternatives. proved highly diagnosing burden, offering a practical solution bridge advancements

Язык: Английский

---

Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer’s Disease in Blood

Biosensors, Год журнала: 2025, Номер 15(2), С. 85 - 85

Опубликована: Фев. 4, 2025

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder and significant cause of dementia in elderly individuals, with growing prevalence our aging population. Extracellular amyloid-β peptides (Aβ), intracellular tau proteins, their phosphorylated forms have gained prominence as critical biomarkers for early precise diagnosis AD, correlating progression response to therapy. The high costs invasiveness conventional diagnostic methods, such positron emission tomography (PET) magnetic resonance imaging (MRI), limit suitability large-scale or routine screening. However, electrochemical (EC) analysis methods made progress detection due sensitivity, excellent specificity, portability, cost-effectiveness. This article reviews the EC biosensing technologies, focusing on protein blood (a low-invasive, accessible medium). then discusses various sensing platforms, including fabrication processes, (LOD), clinical potential show role these sensors transformers changing face AD diagnostics.

Язык: Английский

---

Late-onset epilepsy clinic: From clinical diagnostics to biomarkers

Seizure, Год журнала: 2024, Номер unknown

Опубликована: Июнь 1, 2024

Язык: Английский

---

Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer’s Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(9), С. 4594 - 4594

Опубликована: Апрель 23, 2024

We compared the clinical and analytical performance of Alzheimer’s disease (AD) plasma biomarkers measured using single-molecule array (Simoa) Lumipulse platforms. quantified levels amyloid beta 42 (Aβ42), Aβ40, phosphorylated tau (Ptau181), total in 81 patients with mild cognitive impairment (MCI), 30 AD, 16 non-AD dementia. found a strong correlation between Simoa methods. Concerning diagnosis, Ptau181/Aβ42 (AUC 0.739, 95% CI 0.592–0.887) Aβ42 0.735, 0.589–0.882 AUC 0.733, 0.567–0.900) had highest discriminating power. However, their power was significantly lower than that CSF Aβ42/Aβ40, as by 0.879, 0.766–0.992). Ptau181 were markers most consistent Aβ42/Aβ40 status 0.801, 0.712–0.890 vs. 0.870, 0.806–0.934, respectively) at ≥2.127 ≥0.084 cut-offs, respectively. The AD assays is weaker biomarkers. At present, analysed may be useful for screening to reduce number lumbar punctures setting.

Язык: Английский

---

Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review

Brain Communications, Год журнала: 2024, Номер 6(6)

Опубликована: Янв. 1, 2024

Astrocytes are fundamental in neural functioning and homeostasis the central nervous system. These cells respond to injuries pathological conditions through astrogliosis, a reactive process associated with neurodegenerative diseases such as Alzheimer's disease. This is thought begin early stages of these conditions. Glial fibrillary acidic protein (GFAP), type III intermediate filament predominantly expressed astrocytes, has emerged key biomarker for monitoring this response. During GFAP released into biofluids, making it candidate non-invasive diagnosis tracking diseases. Growing evidence positions disease specificity disease-correlation characteristics comparable established clinical markers, Aβ peptides phosphorylated tau protein. To improve diagnostic accuracy, particularly presence confounders comorbidities, incorporating panel biomarkers may be advantageous. review will explore potential within panel, examining its role diagnosis, progression integration practice management.

Язык: Английский

---